Literature DB >> 17999388

p53 regulates FAK expression in human tumor cells.

Vita M Golubovskaya1, Richard Finch, Frederick Kweh, Nicole A Massoll, Martha Campbell-Thompson, Margaret R Wallace, William G Cance.   

Abstract

Attenuation of the p53 protein is one of the most common abnormalities in human tumors. Another important marker of tumorigenesis is focal adhesion kinase (FAK), a 125-kDa tyrosine kinase that is overexpressed at the mRNA and protein levels in a variety of human tumors. FAK is a critical regulator of adhesion, motility, metastasis, and survival signaling. We have characterized the FAK promoter and demonstrated that p53 can inhibit the FAK promoter activity in vitro. In the present study, we showed that p53 can bind the FAK promoter-chromatin region in vivo by chromatin immunoprecipitation (ChIP) assay. Furthermore, we demonstrated down-regulation of FAK mRNA and protein levels by adenoviral overexpression of p53. We introduced plasmids with different mutations in the DNA-binding domain of p53 (R175H, p53 R248W and R273H) into HCTp53(-/-) cells and showed that these mutations of p53 did not bind FAK promoter and did not inhibit FAK promoter activity, unlike wild type p53. We analyzed primary breast and colon cancers for p53 mutations and FAK expression, and showed that FAK expression was increased in tumors containing mutations of p53 compared to tumors with wild type p53. In addition, tumor-derived missense mutations in the DNA-binding domain (R282, R249, and V173) also led to increased FAK promoter activity. Thus, the present data show that p53 can regulate FAK expression during tumorigenesis. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17999388      PMCID: PMC4562219          DOI: 10.1002/mc.20395

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  21 in total

1.  pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions.

Authors:  M D Schaller; C A Borgman; B S Cobb; R R Vines; A B Reynolds; J T Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

2.  A global map of p53 transcription-factor binding sites in the human genome.

Authors:  Chia-Lin Wei; Qiang Wu; Vinsensius B Vega; Kuo Ping Chiu; Patrick Ng; Tao Zhang; Atif Shahab; How Choong Yong; YuTao Fu; Zhiping Weng; JianJun Liu; Xiao Dong Zhao; Joon-Lin Chew; Yen Ling Lee; Vladimir A Kuznetsov; Wing-Kin Sung; Lance D Miller; Bing Lim; Edison T Liu; Qiang Yu; Huck-Hui Ng; Yijun Ruan
Journal:  Cell       Date:  2006-01-13       Impact factor: 41.582

Review 3.  The complexity of p53 modulation: emerging patterns from divergent signals.

Authors:  A J Giaccia; M B Kastan
Journal:  Genes Dev       Date:  1998-10-01       Impact factor: 11.361

4.  Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.

Authors:  Charles S Smith; Vita M Golubovskaya; Erin Peck; Li-Hui Xu; Brett P Monia; Xihui Yang; William G Cance
Journal:  Melanoma Res       Date:  2005-10       Impact factor: 3.599

5.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

6.  Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.

Authors:  Kathleen Conway; Sharon N Edmiston; Lisa Cui; S Scott Drouin; Jingzhong Pang; Mei He; Chiu-Kit Tse; Joseph Geradts; Lynn Dressler; Edison T Liu; Robert Millikan; Beth Newman
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

Review 7.  The role of focal-adhesion kinase in cancer - a new therapeutic opportunity.

Authors:  Gordon W McLean; Neil O Carragher; Egle Avizienyte; Jeff Evans; Valerie G Brunton; Margaret C Frame
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

Review 8.  Restoring p53-dependent tumor suppression.

Authors:  Wenge Wang; Farzan Rastinejad; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

9.  Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites.

Authors:  Vita Golubovskaya; Aparna Kaur; William Cance
Journal:  Biochim Biophys Acta       Date:  2004-05-25

10.  Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly.

Authors:  K Burridge; C E Turner; L H Romer
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  51 in total

1.  Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Authors:  Wendy L Allen; Richard C Turkington; Leanne Stevenson; Gail Carson; Vicky M Coyle; Suzanne Hector; Philip Dunne; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Mol Cancer Ther       Date:  2012-06-04       Impact factor: 6.261

Review 2.  High-throughput screening strategies for targeted identification of therapeutic compounds in colorectal cancer.

Authors:  Agnieszka B Bialkowska; Vincent W Yang
Journal:  Future Oncol       Date:  2012-03       Impact factor: 3.404

3.  A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Authors:  Vita M Golubovskaya; Sheila Figel; Baotran T Ho; Christopher P Johnson; Michael Yemma; Grace Huang; Min Zheng; Carl Nyberg; Andrew Magis; David A Ostrov; Irwin H Gelman; William G Cance
Journal:  Carcinogenesis       Date:  2012-03-07       Impact factor: 4.944

4.  Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Authors:  Baotran Ho; Gretchen Olson; Sheila Figel; Irwin Gelman; William G Cance; Vita M Golubovskaya
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

5.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA.

Authors:  Jie Ding; Shenglin Huang; Shunquan Wu; Yingjun Zhao; Linhui Liang; Mingxia Yan; Chao Ge; Jian Yao; Taoyang Chen; Dafang Wan; Hongyang Wang; Jianren Gu; Ming Yao; Jinjun Li; Hong Tu; Xianghuo He
Journal:  Nat Cell Biol       Date:  2010-03-21       Impact factor: 28.824

6.  TGF-beta1 modulates focal adhesion kinase expression in rat intestinal epithelial IEC-6 cells via stimulatory and inhibitory Smad binding elements.

Authors:  Mary F Walsh; Dinakar R Ampasala; Arun K Rishi; Marc D Basson
Journal:  Biochim Biophys Acta       Date:  2008-11-14

7.  Negative control of CSL gene transcription by stress/DNA damage response and p53.

Authors:  Elena Menietti; Xiaoying Xu; Paola Ostano; Jean-Marc Joseph; Karine Lefort; G Paolo Dotto
Journal:  Cell Cycle       Date:  2016-05-10       Impact factor: 4.534

8.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

Review 9.  Contribution of p53 to metastasis.

Authors:  Emily Powell; David Piwnica-Worms; Helen Piwnica-Worms
Journal:  Cancer Discov       Date:  2014-03-21       Impact factor: 39.397

10.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Authors:  Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.